Results 41 to 50 of about 87,478 (258)

Oxygen‐Tunnel Indium Tin Oxide Vertical Channel Transistors with Enhanced Current Density and Reliability for Monolithic 3D Compute‐In‐Memory Systems

Advanced Functional Materials, EarlyView.
Oxygen‐tunnel (OT) indium tin oxide (ITO) vertical channel transistors (VCTs) enable reliable, high‐density gain‐cell memory for monolithic 3D integration. A sandwiched SiN/SiO2/SiN OT stack selectively regulates oxygen transport, suppressing parasitic electrode oxidation while stabilizing channel oxygen vacancies, thereby suppressing carrier injection
Hyeonho Gu, Haksoon Jung, Yongwoo Lee, Hoichang Jeong, Yanfeng Zhao, Heesoo Yang, Minho Park, Hyeonjin Lee, Seunghun Baek, Minju Song, Junghwan Kim, Youngmin Jo, Hyunjin Park, Munhyeon Kim, Jae‐Joon Kim, Kyuho Jason Lee, Byungjo Kim, Jimin Kwon   +17 more
wiley   +1 more source

Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.

PLoS ONE, 2020
BackgroundPakistan is among top five high burden countries for tuberculosis and drug resistant TB. Among rifampicin sensitive new pulmonary TB (PTB), prevalence of isoniazid resistance is 8.3% (95%CI: 7.0-10.7) and resistance to fluoroquinolone is higher
Sabira Tahseen, Faisal Masood Khanzada, Alamdar Hussain Rizvi, Mahmood Qadir, Aisha Ghazal, Aurangzaib Quadir Baloch, Tehmina Mustafa   +6 more
doaj   +1 more source

Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial

The Lancet Microbe, 2020
Summary: Background: Clinical studies suggest that isoniazid contributes rapid bacterial killing during the initial 2 days of tuberculosis treatment, but that the activity of isoniazid declines substantially after day 3 of treatment.
Andreas Diacon, ProfPhD, Sachiko Miyahara, PhD, Rodney Dawson, PhD, Xin Sun, PhD, Evelyn Hogg, Kathleen Donahue, MA, Michael Urbanowski, PhD, Veronique De Jager, MD, Courtney V Fletcher, ProfPharmD, Richard Hafner, MD, Susan Swindells, ProfMBBS, William Bishai, ProfMD   +11 more
doaj   +1 more source

Breast tuberculosis in Northeast Iran: Review of 22 cases [PDF]

, 2014
Background: Breast tuberculosis (breast TB) is an extremely rare disease, so case reviews are also rare.Methods: This study is a retrospective review of patients with breast TB who were treated between 2002 and 2012 at the Health Center of Gorgan City ...
Khodabakhshi, B., Mehravar, F.
core   +2 more sources

Dual‐Peptide Nanoplatform: Mesoporous Silica Nanoparticles Functionalized With a Cell‐Penetrating Peptide and Loaded With Rationally Designed Antimicrobial Peptides for Tuberculosis Therapy

Advanced Healthcare Materials, Volume 15, Issue 21, 5 June 2026.
Machine learning–guided engineering of a plectasin‐derived peptide yields DC05, a potent antimycobacterial candidate. Encapsulation into tuftsin‐functionalized mesoporous silica nanoparticles enhances intracellular delivery, stability, and activity against Mycobacterium tuberculosis while maintaining low cytotoxicity and minimal hemolysis. The combined
Christian S. Carnero Canales, Cesar Augusto Roque‐Borda, Ana Carolina Cerqueira Negri, Oswaldo Ramirez Delgado, Letícia Oliveira Catarin Nunes, Flávia Aparecida Resende, Hernane Barud, Norival Alves Santos‐Filho, Saulo Santesso Garrido, Karen Cristina Oliveira, Alexandra Ivo de Medeiros, Rafael Miguel Sábio, Fernando Rogério Pavan   +12 more
wiley   +1 more source

Lansoprazole Ameliorates Isoniazid-Induced Liver Injury

Pharmaceuticals
Isoniazid is a first-line drug in antitubercular therapy. Isoniazid is one of the most commonly used drugs that can cause liver injury or acute liver failure, leading to death or emergency liver transplantation.
Eri Wakai, Takashi Shiromizu, Shota Otaki, Junko Koiwa, Satoshi Tamaru, Yuhei Nishimura   +5 more
doaj   +1 more source

Short-Course Chemotherapy for Tuberculosis [PDF]

, 2005
Annotated and edite transcript of a Witness Seminar held on 3 February 2004. Introduction by Dr Linda Bryder, University of Auckland.First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2005. ©The Trustee of the Wellcome Trust,
Christie, DA, Tansey, EM
core  

Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.

, 2012
BACKGROUND: Treatment options for drug-resistant tuberculosis (DR-TB) are limited. Linezolid has been successfully used to treat DR-TB in adults, but there are few case reports of its use in children for TB.
Hallbauer, UM, Hesseling, AC, Rose, PC, Schaaf, HS, Seddon, JA   +4 more
core   +1 more source

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

Advanced Materials, EarlyView.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa, Gracia Mendoza, Silvia Irusta, Manuel Arruebo   +3 more
wiley   +1 more source

Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India

Saudi Pharmaceutical Journal, 2020
Isoniazid is the most commonly used drug for treatment of tuberculosis, and is administered individually or in combination with other drugs as standard first line therapy.
Faisal Imam, Manju Sharma, Khalid Umer Khayyam, Mohammad Rashid Khan, Mohammad Daud Ali, Wajhul Qamar   +5 more
doaj   +1 more source